Literature DB >> 25778862

Association of P2RY12 polymorphisms with eosinophil and platelet activation in patients with aspirin-exacerbated respiratory disease.

Purevsuren Losol1, Nami Shrestha Palikhe2, Ji Won Lee3, Sailesh Palikhe1, Mi-Ae Kim4, Eun-Mi Yang5, Hyunna Choi5, Gil-Soon Choi6, Seung-Hyun Kim5, Hae-Sim Park7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25778862     DOI： 10.1016/j.anai.2015.02.009

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  3 in total

Review 1.  What we know about nonsteroidal anti-inflammatory drug hypersensitivity.

Authors:  Duy Le Pham; Ji-Hye Kim; Tu Hoang Kim Trinh; Hae-Sim Park
Journal:  Korean J Intern Med       Date:  2016-03-31       Impact factor: 2.884

2.  A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Katherine N Cahill; Juan Carlos Cardet; Katherine Murphy; Jing Cui; Brittney Dioneda; Parul Kothari; Benjamin A Raby; Elliot Israel; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-06-08       Impact factor: 10.793

3.  P2Y12 antagonist attenuates eosinophilic inflammation and airway hyperresponsiveness in a mouse model of asthma.

Authors:  Dong-Hyeon Suh; Hoang Kim Tu Trinh; Jing-Nan Liu; Le Duy Pham; Sang Myun Park; Hae-Sim Park; Yoo Seob Shin
Journal:  J Cell Mol Med       Date:  2015-11-27       Impact factor: 5.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.